Product Description
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bangladesh | Brazil | Bulgaria | China | Dominican Republic | Egypt | India | Indonesia | Ireland | Italy | Korea | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Slovenia | South Africa | Sri Lanka | Taiwan | Tunisia | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Med. Univ. Wien, Uk für Innere Medizin I
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Abscess
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2011-002758-29 | P4 |
Completed |
Unknown |
2013-10-04 |
|
abscess-cef-moxi | P4 |
Completed |
Abscess |
2009-12-01 |